Irbesartán/Hidroclorotiazida Combix (Hydrochlorothiazide, Irbesartan)

Irbesartan/Hydrochlorothiazide is indicated for hypertension, acting on the renin‑angiotensin system and renal sodium handling.

• Hypertension: reduces systolic and diastolic blood pressure, helping achieve target levels.
• Essential hypertension: provides consistent blood pressure control in patients with primary hypertension.
• Secondary hypertension: assists in managing blood pressure when caused by renal or endocrine disorders.

• Irbesartan selectively blocks the AT1 subtype of angiotensin II receptors, preventing vasoconstriction and aldosterone‑mediated sodium retention. Hydrochlorothiazide inhibits the NaCl cotransporter in the distal convoluted tubule, increasing urinary excretion of sodium and water and lowering plasma volume. The combined actions produce additive blood‑pressure‑lowering effects, resulting in reduced peripheral resistance and improved cardiovascular outcomes.

The combination may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dizziness or light‑headedness.
• Headache.
• Increased urination.
• Electrolyte disturbances such as low potassium.
• Fatigue.
• Mild gastrointestinal discomfort.

Serious or Rare Side Effects

• Severe dehydration or electrolyte imbalance.
• Acute kidney injury or worsening renal function.
• Hyperkalemia leading to cardiac arrhythmia.
• Allergic reactions including rash, angioedema, or anaphylaxis.
• Severe hypotension causing fainting.
• Hepatic dysfunction with jaundice.

Before initiating therapy, clinicians should consider several safety aspects.

• Renal function: monitor serum creatinine and eGFR regularly.
• Electrolytes: check potassium and sodium levels periodically.
• Pregnancy: contraindicated in pregnancy (Category D) due to fetal risk.
• Elderly: start at lower dose and monitor for orthostatic hypotension.
• Drug interactions: review concomitant medications for additive effects.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Irbesartan/Hydrochlorothiazide can interact with several drug classes; awareness helps avoid adverse outcomes.

Major Interactions (Avoid)

• ACE inhibitors: increased risk of hyperkalemia and renal impairment.
• Potassium‑sparing diuretics: may cause dangerous hyperkalemia.
• Lithium: concurrent use can raise lithium levels and toxicity.

Moderate Interactions (Monitor Closely)

• NSAIDs: may blunt antihypertensive effect and affect renal function.
• Other antihypertensives: additive hypotensive effect requires dose adjustment.
• CYP2C9 inhibitors (e.g., fluconazole): can raise irbesartan plasma concentrations.